In a recent opinion piece, Incubate Executive Director John Stanford and Senator Thom Tillis (R-NC) took to the pages of Fortune with a clear warning: America’s leadership in life sciences innovation is not guaranteed. Policies that undermine intellectual property protections, distort market incentives, or inject uncertainty into the biotech ecosystem risk driving investment -- and the next generation of cures -- overseas. As global competitors aggressively court biotech cap

This month, Incubate executive director John Stanford's conversation with Senator Thom Tillis (R-NC) on the Making Medicine Podcast was featured in RealClearHealth , IAM Media , and IP Watchdog . Sen. Tillis called for aggressive measures to counter China's growing economic influence, particularly in life sciences innovation, highlighting the need to pass the Patent Eligibility Restoration Act to address what he described as the current law's chilling effect on innovation: "

WASHINGTON (December 4) -- This week, U.S. Senator Thom Tillis (R-NC) warned that addressing foreign drug pricing disparities and strengthening U.S. intellectual property protections are essential to preserving the nation's global leadership in life sciences. In a new episode of the Making Medicine podcast with Incubate's executive director John Stanford, Tillis detailed a range of urgent policy priorities to maintain America's edge in biotech. He argued that burdensome re

Incubate executive director John Stanford recently sat down with Joshua Kresh for an episode of the Making Medicine podcast to talk about all things intellectual property (IP). Kresh leads the Institute for Progress & Innovation (IPPI) , where he focuses on strengthening the policies that support scientific progress. IP underpins everything from movies and music to, most importantly, the medicines we rely on. Drug development is slow, risky, and enormously expensive, often t

Incubate has urged Congress to take action and ensure the 2025 Special 301 Report reaffirms America’s commitment to safeguarding...

Read Incubate's blog on the recently announced March-In proposal. Incubate recently submitted a comment letter intended to educate...

An Open Letter to Members of Congress and the Biden Administration from Leaders in the Life Sciences Community As leaders... An Open...

Incubate and DLA Piper hosted a breakfast panel at this year's J.P. Morgan Healthcare Conference in San Francisco, California. Incubate...

After a nine-month review, the Biden administration has reached the unprecedented and misguided conclusion that the 1980 Bayh-Dole Act...

In late August, the Centers for Medicare & Medicaid Services announced the first 10 drugs that will be subject to Medicare price setting...

The small-molecule penalty "doesn't create the right incentives for where we want to go with the Cancer Moonshot or driving cures," Mohit...

Executive Director John Stanford testified before the International Trade Organization.

The drug pricing debate is a worthy one. We have to have open discussions about maximizing innovation and access. But half-written...